The global stem cell therapy market valued USD 306.1 million in 2023, which is expected to reach USD 910.8 million by 2030, progressing with a CAGR of 16.9% during 2024–2030. This is attributed to the extensive research being conducted on stem cell therapy. For instance, a study published in a journal, named Nature Medicine, in January 2023 mentions that in patients transplanted with the largest number of neural stem cells, brain atrophy significantly reduced and the pro-generative cerebrospinal fluid profile varied post treatment.
In addition, researchers at the IRCCS San Raffaele Scientific Institute have demonstrated that the treatment is safe and well tolerated by the body. In their study, transplanting stem cells extracted from fetuses into the spinal cord of MS patients increased the concentration of neuroprotective molecules in the spine.
Such extensive research is being enabled by the rising funding in this area. For instance, in January 2022, Cellino Biotech Inc., which manufactures autonomous cell therapies, closed its Series A financing round, worth USD 80 million, with Leaps by Bayer as the lead investor and Humboldt Fund and 8VC being the other contributors. The funding will allow Cellino to widen the availability of stem cell therapies and establish a foundry for autonomous human cells by 2025.
Allogeneic stem cell therapy accounts for the largest share, and this category is expected to grow significantly during 2024–2030. This is because of an increase in the number of studies on allogeneic stem cell therapy. Furthermore, companies providing cell therapies are more focused on the development of allogeneic cell therapy products.
The autologous therapy category is projected to witness significant growth during the forecast period because of the advantages of this treatment, such as a low risk of organ rejection. Autologous stem cell transplants are given to people who have been prescribed high-dose radiation and chemotherapy.
Stem cell therapy is majorly used in the treatment of musculoskeletal disorders, because of the high prevalence of conditions such as osteoarthritis, lower-back injuries, and strains. Moreover, a number of studies are underway to evaluate the potential of stem cell therapy for people suffering from issues of the bones and muscles.
North America is expected to grow at a CAGR of 16.8% during 2024–2030, because of the increasing funding being received by CROs, academic institutions, and market players for conducting research on this topic. For instance, in September 2022, the University of California San Diego received USD 150 million to expand stem cell and regenerative medicine research.
Asia-Pacific is the fastest-growing region, attributed to the increasing expenditure in healthcare, specifically, R&D on advanced treatments. For instance, in August 2022, the University of Sydney announced the receipt of a USD-478 million investments for building a biomedical precinct, which would help fast-track healthcare research. Scientists will conduct research on new drugs, regenerative medicine, medical device development, and stem cell therapy.
Some of the key players operating in the market are Smith & Nephew plc, MEDIPOST Co. Ltd., Anterogen Co. Ltd., CORESTEM Inc., PHARMICELL Co., Ltd, NuVasive Inc., RTI Surgical Inc., AlloSource, JCR Pharmaceutical Co. Ltd., and Takeda Pharmaceutical Company Limited.